AIM
IOVA icon

Acrospire Investment Management’s Iovance Biotherapeutics IOVA Stock Holding History

Acrospire Investment Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,584
Closed -$13K – 2315
2016
Q3 		$13K Sell
1,584
-2,600
-62% -$22K 0.01% 1631
2016
Q2 		$34K Buy
+4,184
New +$26.3K 0.03% 1311

Other funds holding IOVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acrospire Investment Management's IOVA Position: Q4 2016 in Review

Acrospire Investment Management sold out of Iovance Biotherapeutics (IOVA) in Q4 2016, closing a stake of 1,584 shares — an estimated $13K sold.

Acrospire Investment Management first reported a position in IOVA in Q2 2016 and held it in 2 quarters. The position peaked at $34K in Q2 2016. 87 funds tracked by Wall St. Rank hold IOVA as of Q4 2016.

  • Acrospire Investment Management reported no remaining Iovance Biotherapeutics position as of Q4 2016 after selling out during the quarter.
  • Acrospire Investment Management sold 1,584 Iovance Biotherapeutics shares in Q4 2016, an estimated $13K.
  • Acrospire Investment Management first reported a position in Iovance Biotherapeutics in Q2 2016 and held it in 2 quarters.
  • Acrospire Investment Management's Iovance Biotherapeutics position peaked at $34K in Q2 2016.
  • 87 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2016.

Based on Acrospire Investment Management's 13F filing for Q4 2016, filed 14 Feb 2017.